Drug Trial Radar · NCT06523556
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
49
Planned (sponsor's estimate)
Start
Aug 2, 2024
Primary completion
Oct 31, 2027
Study completion Oct 31, 2028
Sponsor
- Lead sponsor
- Uma BorateAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Incyte Corporation
- First posted
- Jul 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase Ib/II trial tests the best dose of axatilimab and effectiveness of axatilimab with or without azacitidine for the treatment of patients with advanced phase myeloproliferative neoplasms (MPN), myeloproliferative neoplasm/myelodysplastic syndrome (MPN/MDS) overlap or high risk chronic myelomonocytic leukemia (CMML). Axatilimab is an antibody that is cloned from a single white blood cell that is known to be able to recognize cancer cells and block a protein on the surface of the white blood cells that may be involved in cancer cell growth. By blocking the proteins, this may slow or halt the growth of the cancer. Azacitidine is in a class of medications called antimetabolites. It works by stopping or slowing the growth of cancer cells. Giving axatilimab with or without azacitidine may be safe and effective in treating patients with advanced phase MPN, MPN/MDS overlap or high risk CMML.
Conditions
- Atypical Chronic Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic/Myeloproliferative Neoplasm
- Recurrent Myelodysplastic/Myeloproliferative Neoplasm
- Recurrent Myeloproliferative Neoplasm
- Refractory Chronic Myelomonocytic Leukemia
- Refractory Myelodysplastic/Myeloproliferative Neoplasm
- Refractory Myeloproliferative Neoplasm
Interventions
AxatilimabBiological
Given IV
AzacitidineDrug
Given IV or SC
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow Aspiration and BiopsyProcedure
Undergo bone marrow biopsy and aspiration
Survey AdministrationOther
Ancillary study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicitiesTime frame: Up to 42 days after the first dose of study medication
- Overall response rateTime frame: Up to 5 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.